$IRD
Opus Genetics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000114036122040029 Filed on November 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $39.85M $0.00 $489.0K
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.054M $1.703M $1.595M
YoY Change 45.26% 6.77% 17.28%
% of Gross Profit
Research & Development $3.586M $2.835M $0.00
YoY Change -24.28% -100.0%
% of Gross Profit
Depreciation & Amortization $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $5.640M $4.538M $0.00
YoY Change -8.29% -100.0%
Operating Profit -$4.538M -$4.232M
YoY Change 7.23% 181.03%
Interest Expense $46.00K $0.00 $0.00
YoY Change -2400.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $7.000K $2.000K
YoY Change -100.0% 250.0% -98.05%
Pretax Income $34.26M -$4.531M -$4.230M
YoY Change -642.63% 7.12% 201.39%
Income Tax $315.0K $0.00 $0.00
% Of Pretax Income 0.92%
Net Earnings $33.94M -$4.531M -$4.230M
YoY Change -637.64% 7.12% 238.94%
Net Earnings / Revenue 85.17% -865.03%
Basic Earnings Per Share -$0.22 -$0.25
Diluted Earnings Per Share $1.58 -$0.22 -$249.9K
COMMON SHARES
Basic Shares Outstanding 20.81M 20.58M 16.93M
Diluted Shares Outstanding 20.50M 16.93M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.68M $13.96M $22.63M
YoY Change 72.44% -38.34% 180.11%
Cash & Equivalents $42.60M $13.86M $22.25M
Short-Term Investments $49.00K $101.0K $383.0K
Other Short-Term Assets $80.00K $61.00K $46.00K
YoY Change 12.68% 32.61% -91.93%
Inventory
Prepaid Expenses $1.373M $544.0K $514.0K
Receivables $1.298M
Other Receivables $0.00
Total Short-Term Assets $48.99M $14.56M $23.19M
YoY Change 87.92% -37.22% 168.03%
LONG-TERM ASSETS
Property, Plant & Equipment $6.000K $7.000K $11.00K
YoY Change -40.0% -36.36% -92.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $6.000K $7.000K $11.00K
YoY Change -40.0% -36.36% -93.91%
TOTAL ASSETS
Total Short-Term Assets $48.99M $14.56M $23.19M
Total Long-Term Assets $6.000K $7.000K $11.00K
Total Assets $48.99M $14.57M $23.20M
YoY Change 87.87% -37.22% 162.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.069M $1.468M $1.434M
YoY Change -32.51% 2.37% -22.07%
Accrued Expenses $1.684M $1.223M $1.204M
YoY Change -2.83% 1.58% 136.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.753M $2.691M $2.638M
YoY Change -28.59% 2.01% -12.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.753M $2.691M $2.638M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.753M $2.691M $2.638M
YoY Change -28.59% 2.01% -15.44%
SHAREHOLDERS EQUITY
Retained Earnings -$71.48M -$105.4M
YoY Change -20.02%
Common Stock $2.000K $2.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $46.24M $11.88M $20.57M
YoY Change
Total Liabilities & Shareholders Equity $48.99M $14.57M $23.20M
YoY Change 87.87% -37.22% 162.68%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income $33.94M -$4.531M -$4.230M
YoY Change -637.64% 7.12% 238.94%
Depreciation, Depletion And Amortization $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0% 0.0%
Cash From Operating Activities $28.79M -$4.498M -$3.584M
YoY Change -609.94% 25.5% 217.17%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -12.00K 1.328M 1.600M
YoY Change -100.15% -17.0%
NET CHANGE
Cash From Operating Activities 28.79M -4.498M -3.584M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities -12.00K 1.328M 1.600M
Net Change In Cash 28.78M -3.170M -1.984M
YoY Change 1160.03% 59.78% 75.58%
FREE CASH FLOW
Cash From Operating Activities $28.79M -$4.498M -$3.584M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
CY2021Q1 ocup Adjustments To Additional Paid In Capital Reclassification Of Warrants To Equity
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity
61793000
CY2021Q2 ocup Stock Issued During Period Value In Connection With Registered Direct Offering
StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering
15000000
CY2021Q2 ocup Stock Issued During Period Value In Settlement With Investors
StockIssuedDuringPeriodValueInSettlementWithInvestors
1614000
CY2021Q2 ocup Stock Issued During Period Value Stock Exercise Of Warrants
StockIssuedDuringPeriodValueStockExerciseOfWarrants
0
CY2022Q1 ocup Stock Issued During Period Value At The Market Program
StockIssuedDuringPeriodValueAtTheMarketProgram
1208000
ocup Share Settlement With Investors
ShareSettlementWithInvestors
0
ocup Proceeds From Issuance Of Common Stock In Connection With Registered Direct Offering
ProceedsFromIssuanceOfCommonStockInConnectionWithRegisteredDirectOffering
0
ocup Proceeds From Issuance Of Common Stock In Connection With Registered Direct Offering
ProceedsFromIssuanceOfCommonStockInConnectionWithRegisteredDirectOffering
15000000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
dei Entity Address Address Line1
EntityAddressAddressLine1
37000 Grand River Avenue, Suite 120
dei Entity Address City Or Town
EntityAddressCityOrTown
Farmington Hills
dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48335
dei City Area Code
CityAreaCode
248
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34079
dei Entity Registrant Name
EntityRegistrantName
Ocuphire Pharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3516358
dei Local Phone Number
LocalPhoneNumber
681-9815
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
OCUP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
0
CY2021Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
538000
ocup Noncash Or Part Noncash Reclassification Of Warrants To Equity Amount
NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount
0
ocup Noncash Or Part Noncash Reclassification Of Warrants To Equity Amount
NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount
61793000
ocup Number Of Small Molecule Product Candidates
NumberOfSmallMoleculeProductCandidates
2
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
13400000
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2021Q3 ocup Number Of Potential Milestones
NumberOfPotentialMilestones
0
ocup Contingent Value Rights Payment Period
ContingentValueRightsPaymentPeriod
P15Y
CY2020Q4 ocup Percentage Of Cash Consideration Payment
PercentageOfCashConsiderationPayment
0.75
ocup Contingent Value Rights Ip Term
ContingentValueRightsIPTerm
P10Y
CY2022Q3 ocup Number Of Milestones Accrued
NumberOfMilestonesAccrued
0
CY2021Q2 ocup Number Of Potential Milestones
NumberOfPotentialMilestones
0
CY2022Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
CY2021Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-33829000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000
CY2022Q2 ocup Stock Issued During Period Value At The Market Program
StockIssuedDuringPeriodValueAtTheMarketProgram
1858000
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001228627
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20807015
CY2021Q3 ocup Stock Issued During Period Value At The Market Program
StockIssuedDuringPeriodValueAtTheMarketProgram
1739000
CY2021Q3 ocup Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
50000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
478000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
76000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4230000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
20566000
CY2022Q3 ocup Stock Issued During Period Value At The Market Program
StockIssuedDuringPeriodValueAtTheMarketProgram
1362000
CY2022Q3 ocup Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
42000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
493000
CY2022Q3 ocup Stock Issued During Period Value Stock Exercise Of Warrants
StockIssuedDuringPeriodValueStockExerciseOfWarrants
0
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4531000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
11877000
ocup Share Settlement With Investors
ShareSettlementWithInvestors
1614000
ocup Income Loss From Investments Related To License Agreement
IncomeLossFromInvestmentsRelatedToLicenseAgreement
0
ocup Income Loss From Investments Related To License Agreement
IncomeLossFromInvestmentsRelatedToLicenseAgreement
289000
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P7M
ocup Operating Leases Monthly Base Rent
OperatingLeasesMonthlyBaseRent
3000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
9000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
9000
us-gaap Operating Lease Cost
OperatingLeaseCost
30000
us-gaap Operating Lease Cost
OperatingLeaseCost
107000
CY2022Q3 ocup Lessee Operating Lease Liability Payments Due Next15 Months
LesseeOperatingLeaseLiabilityPaymentsDueNext15Months
45000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
544000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1243000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
61000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
71000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
605000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1314000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10000
CY2021Q3 us-gaap Depreciation
Depreciation
1000
CY2022Q3 us-gaap Depreciation
Depreciation
1000
us-gaap Depreciation
Depreciation
3000
us-gaap Depreciation
Depreciation
3000
CY2022Q3 ocup Accrued Research And Development Services And Supplies Current
AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
583000
CY2021Q4 ocup Accrued Research And Development Services And Supplies Current
AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
1081000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
380000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
488000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
186000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
84000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
74000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
80000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1223000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1733000
CY2021Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
600000
ocup Debt Instrument Number Of Installments
DebtInstrumentNumberOfInstallments
6
CY2022Q3 us-gaap Short Term Debt Percentage Bearing Fixed Interest Rate
ShortTermDebtPercentageBearingFixedInterestRate
0.055
us-gaap Interest Expense
InterestExpense
9000
ocup Number Of Directors Signed Waiver Agreements
NumberOfDirectorsSignedWaiverAgreements
6
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
493000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
478000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1383000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1435000
CY2022Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
52225
CY2022Q3 ocup Number Of Board Members Granted Stock Awards For Services
NumberOfBoardMembersGrantedStockAwardsForServices
4
CY2021Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
5047
CY2021Q3 ocup Number Of Board Members Granted Stock Awards For Services
NumberOfBoardMembersGrantedStockAwardsForServices
2
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
74396
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
14444
CY2022Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
99000
CY2021Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
26000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
154000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
82000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001140361-22-040029-index-headers.html Edgar Link pending
0001140361-22-040029-index.html Edgar Link pending
0001140361-22-040029.txt Edgar Link pending
0001140361-22-040029-xbrl.zip Edgar Link pending
brhc10043598_10q.htm Edgar Link pending
brhc10043598_ex10-1.htm Edgar Link pending
brhc10043598_ex31-1.htm Edgar Link pending
brhc10043598_ex31-2.htm Edgar Link pending
brhc10043598_ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ocup-20220930.xsd Edgar Link pending
R1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ocup-20220930_cal.xml Edgar Link unprocessable
ocup-20220930_def.xml Edgar Link unprocessable
ocup-20220930_pre.xml Edgar Link unprocessable
ocup-20220930_lab.xml Edgar Link unprocessable
brhc10043598_10q_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending